Re-entry into the cell cycle from quiescence requires the activation of mitogen-activated protein (MAP) kinases of the extracellular-signal-regulated kinase (ERK) family [1,2]. The relationship between ERK and cell-cycle control is, however, complex, as ERK activation can also lead to terminal differentiation [3] or a senescence-like growth arrest [4] . Here, we report that reversible cell-cycle exit induced by serum withdrawal in primary avian fibroblasts is associated with rapid deactivation of ERK, but ERK activity is subsequently regenerated and sustained at high levels in fully quiescent (G0) cells. As in proliferating cells, ERK activation during G0 required the MAP kinase kinase MEK and was partially dependent on cell adhesion. Active, phosphorylated ERK was concentrated in the nucleus in cycling cells, but was largely confined to the cytoplasm during G0. This was unexpected, as activatory phosphorylation mediated by MEK is thought to play an important role in promoting nuclear translocation [5,6]. These results indicate that transient deactivation of ERK signalling can be sufficient for stable cell-cycle exit, and that MEK-mediated phosphorylation is not sufficient for nuclear translocation of active ERK in G0. Cytoplasmic sequestration may prevent active ERK from accessing critical nuclear cell-cycle targets, thus allowing quiescent or post-mitotic cells to retain ERK activity for other physiological functions.
Results and discussion
We examined the effect of growth-factor withdrawal on ERK activity and cell-cycle progression in chick embryo fibroblasts (CEFs), which express predominantly ERK2 [7] . Transfer of CEF in exponential growth phase (E, Figure 1a ) to low serum (LS) medium led to a rapid loss of active ERK (P-ERK) within 15 minutes, and a progressive reduction in S-phase cells, as determined by bromo-deoxyuridine (BrdU) labelling and flow cytometry (Figure 1b ). This was due to accumulation of cells in G0, as judged by the cessation of retinoblastoma (Rb) protein phosphorylation ( Figure 1a) and loss of the proliferation-specific markers cyclin A and Cdc2 (data not shown, [8] ). Growth arrest was rapid, with a significant decrease in DNA synthesis and accumulation of hypophosphorylated Rb within 12 hours and essentially all of the cells entering G0 within 48 hours (Figure 1a ,b).
Although ERK was rapidly inactivated after transfer to LS medium, activity began to return unexpectedly between 6 and 12 hours and increased progressively until the level of (c) ERK activity in NIH3T3 and Rat-1 cells in growth medium, or 1 and 48 h after transfer to LS medium. Replicate cultures of CEFs in growth medium (containing 10% newborn calf serum and 1% chicken serum) were transferred to low serum medium (containing 0.2% newborn calf serum only) as described previously [8] . Rat-1 and NIH3T3 cells were cultured and treated in essentially the same way but with the omission of chicken serum. At the indicated times, Rb phosphorylation and the percentage of S-phase cells were determined as described previously [8] . Active ERK (P-ERK) was detected using a polyclonal antiserum specific for the dual-phosphorylated, active form (Promega, V8031). Total ERK was visualised using a non-discriminating polyclonal rabbit antiserum (Sigma, M5670). active ERK in the fully quiescent cells was at least as high as in proliferating cells (Figure 1a , compare LS 48 hours with E). That these cultures were reversibly arrested in G0 was evident from the effect of serum stimulation, which induced a rapid, transient activation of ERK and a relatively synchronous cell-cycle re-entry during which the majority (> 85%) of cells re-phosphorylated Rb and synthesised DNA within 20 hours (see Supplementary material). Similar results were obtained using both polyand monoclonal antisera specific for the dual-phosphorylated, active form of ERK, and also when ERK activity was measured biochemically using an immunoprecipitation kinase assay (data not shown). Furthermore, this pattern of regulation was not unique to CEFs, as a similar inactivation of ERK followed by recovery after prolonged growth-factor deprivation was seen in NIH3T3 cells and Rat-1 fibroblasts (Figure 1c ).
The initial rapid deactivation of ERK after serum withdrawal (Figure 1a ) suggested that continuous activation through the Ras-Raf-MEK pathway was necessary to sustain the basal level of ERK activity in cycling cells, presumably by counteracting tonic deactivation by MAP kinase phosphatases [9] . Consistent with this prediction, ERK activity declined rapidly when cycling cells were treated with the MEK inhibitors PD098059 and U0126 (Figure 2a , GM). In growth-factor-deprived cultures, ERK was equally sensitive to inhibition by PD098059 and U0126 (Figure 2a , LS), indicating that MEK activity was also present and required to sustain ERK activity in quiescent cells. In fact, similar levels of MEK and Raf activity were detected in growing and fully quiescent cells, although both declined transiently after transfer to LS medium and then increased at later times in parallel with ERK ( Figure 2b ). This pattern of regulation was also evident at the level of Ras, as similar basal levels of Ras-GTP were detected in growing and quiescent cells in pull-down assays using a glutathione-S-transferase (GST)-Raf fusion protein as an affinity matrix [10] , yet Ras-GTP also diminished transiently after growth-factor withdrawal ( Figure 2b ).
Serum contains multiple soluble ERK-pathway agonists including polypeptide growth factors and lysophosphatidic acid (LPA). Cell adhesion, however, also exerts profound and complex effects on ERK-pathway regulation [11] . Integrin engagement can stimulate ERK directly through both Ras-dependent and Ras-independent mechanisms [11] . Cell adhesion also potentiates activation of ERK by serum and other soluble agonists by enhancing the efficiency of signal propagation downstream of Ras at the level of Raf or MEK [11, 12] . It seemed possible therefore that the regeneration of basal ERK activity after prolonged mitogen deprivation might reflect a switch from predominantly serum-dependent to adhesion-dependent Ras-Raf-MEK activation.
To evaluate this possibility, we investigated the adhesion dependence of ERK activity in growing and quiescent cells by suspension in semi-solid medium. As shown in Figure 2c , suspension culture diminished the basal level of active ERK both in the presence and absence of serum, but there was no evidence that the decline was disproportionately greater in quiescent cells (Figure 2c , compare LS with GM). Growth in suspension also blunted the ability of serum to stimulate ERK activity, which, consistent with previous studies [12] , was associated with impaired activation of MEK (data not shown). Thus, these data argue against adhesion as the principal source of the signal sustaining ERK activity after prolonged mitogen deprivation. Growth in suspension inhibits ERK activity equally in cycling and quiescent CEFs. Active ERK was visualised as described in the legend to Figure 1 . PD098059 and U0126 were used at 50 µM final concentration. Active MEK was detected using an antiserum that specifically recognises the dual-phosphorylated, active form (New England Biolabs, 9121). Quantitation was by laser densitometry of the autoradiograms, using a non-discriminating antibody (New England Biolabs, 9122) to control for loading. Equal amounts of cell extract were precipitated using c-Raf-specific antisera, and Raf kinase activity in the precipitates was measured using a coupled assay, essentially as described [15] . GTP-bound Ras was captured using GST-Raf as an affinity matrix and quantitated by western blotting as described previously [10] . Kinase activity and Ras-GTP levels were quantitated by laser densitometry of the autoradiograms. Cells were cultured in GM and LS medium either attached, or suspended in 0.5% methocel. Where indicated, newborn calf serum (S) was added to 10% for 10 min before harvest. 
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Taken together, these results establish that the basal level of active ERK in both growing and quiescent cells depends on continuous Ras-Raf-MEK signalling, and that a temporary interruption or diminution of this signalling is likely to be the main determinant of the biphasic pattern of ERK regulation during cell-cycle exit. Nevertheless, we cannot rule out a contribution from other mechanisms such as fluctuations in ERK or MEK phosphatase activity. Inhibition of basal ERK activity leads to growth arrest in cycling cells [1, 13] . Therefore, it seems probable that the initial deactivation of ERK is required to initiate cell-cycle withdrawal. Conversely, as modest ERK activation can be sufficient to induce DNA synthesis in growth-arrested cells [4, 14] , these results imply that the ERK activity that is regenerated in quiescent CEFs must be unable to promote cell-cycle progression.
To understand why this might be, we compared the subcellular localisation of active ERK in growing and quiescent cells by confocal immunocytochemistry using a monoclonal antibody specific for the dual-phosphorylated, active form of ERK. This analysis (Figure 3 ) revealed that active ERK was predominantly nuclear in growing cells, but that nuclear staining diminished rapidly after transfer to LS medium and was very weak or absent after 1 hour when ERK activity was undetectable by western blotting (Figure 1a) . The overall level of staining increased after 24 and 48 hours. Active ERK in quiescent cells was largely confined to the cytoplasm, where it appeared as fine speckles or granules that, in some cases, were clearly excluded from the nucleus (Figure 3 ). We are confident that this cytoplasmic staining represents active ERK because, as in growing cells, essentially all staining was eliminated by a short treatment with U0126. Strikingly, this situation was rapidly reversed by serum stimulation, which led to a rapid increase in overall staining and reappearance of active ERK in the cell nucleus within 10 minutes, which correlated with the robust activation detected in biochemical assays (see Supplementary material). Thus, whereas active ERK is concentrated in the nucleus in cycling cells, in quiescent cells it is predominantly confined to the cytoplasm. Subcellular localisation of active ERK in cycling and quiescent CEFs. Cycling CEFs (GM), transferred to LS medium for 1, 6, 24 or 48 h, or quiescent cells maintained in LS medium for 48 h and then exposed to 10% newborn calf serum (+ S) for 10 min, were fixed and the subcellular localisation of active, dual-phosphorylated ERK determined by immunocytochemistry. CEFs were cultured on cover slips under the indicated conditions, fixed in 3.7% formaldehyde in TBS (20 mM Tris-HCl pH 7.6, 140 mM NaCl) and permeabilised using 0.5% triton-X100 in TBS. Active ERK was visualised using a monoclonal antibody specific for ERK phosphorylated on both threonine and tyrosine within the TEY motif (Sigma M8159, 1:100), in combination with biotinylated anti-mouse immunoglobulin G (Vector Laboratories, 1:750) and fluorescein-conjugated streptavidin (Vector Laboratories, 1:100). Stained coverslips were mounted and viewed by confocal microscopy. Nuclei are indicated by white arrows. Where indicated, cells were treated with U0126 for 30 min before fixation.
These findings are unexpected in view of current understanding of the mechanism(s) controlling the subcellular localisation of active ERK. Many studies have reported that activation of the ERK pathway by diverse agonists results in nuclear translocation of the active kinase [6] . Although the mechanisms have not been fully elucidated, there is evidence that ERK can enter the nucleus through both passive diffusion and active transport [5] . Common to these mechanisms, however, is the need to first release ERK from cytoplasmic sequestration, which is thought to result from physical association with MEK [5] . It has recently been proposed that MEK-mediated phosphorylation of ERK on Tyr185 within the TEY regulatory phosphorylation sites is sufficient to disrupt the interaction between MEK and ERK, and thus release ERK from cytoplasmic sequestration [5] . Our results, however, indicate that active ERK that has already been phosphorylated at both of the TEY activatory sites can nevertheless be retained in the cytoplasm. This suggests either the existence of cytoplasmic anchors distinct from MEK that are capable of sequestering active ERK, or that activatory phosphorylation is not sufficient to release ERK from sequestration by MEK in quiescent cells.
Further work will be required to distinguish between these alternatives. The differential localisation of ERK nevertheless provides an attractive explanation for the persistence of active ERK in quiescent cells, as recent work has established that ERK must localise to the nucleus in order to execute its mitogenic function [2] . Thus, cytoplasmic sequestration would be predicted to prevent active ERK accessing critical nuclear cell-cycle regulatory substrates in quiescent cells, effectively neutralising its mitogenic potential. This represents an additional, previously unrecognised, level at which the cell-cycle function of ERK may be modulated during normal growth regulation.
Finally, our observations raise the question of what function ERK might fulfil in quiescent cells. Cell-cycle transitions leading to proliferation and differentiation represent the best-characterised biological functions of the ERK pathway. It is clear, however, that ERK is involved in controlling many other aspects of cell physiology. In particular, there is growing evidence that ERK has important roles in regulating metabolism, cell motility, and in the suppression of apoptosis. Cytoplasmic sequestration may provide a mechanism through which active ERK can be retained and re-deployed for such physiological functions in quiescent or post-mitotic cells.
Supplementary material
Supplementary material including a figure showing ERK regulation during serum-induced cell cycle re-entry from G0 in CEF is available at http://current-biology.com/supmat/supmatin.htm.
